Periodic Health Evaluation

Transcription

1 1

2 2 Periodic Health Evaluation ارزیابی سالمت فردی دکتر نگاه توکلی فرد متخصص پزشکی اجتماعی گروه پزشکی اجتماعی دانشگاه علوم پزشکی اصفهان

3 تاریخچه (PHE) از سال 1960 توجه عمومی به ارزیابی دوره ای سالمت معطوف شد. در سال 1970 راهنمای ارزیابی سالمت تهیه شد و در سطح گسترده اجرا گردید. در این سالها مراجعه به پزشکان خانواده و متخصصین داخلی برای ارزیابی سالمت افزایش یافت اولین بررسی اثر بخشی ارزیابی سالمت از سال 1964 آغاز شد بین نفر سال فالواپ شدند و نشان داده شد که با ارزیابی مورتالیتی و موربیدیتی کاهش می یابد.

4 ارزیابی سالمت فردی در ایران ارزیابی پیش از دبستان )طرح سنجش( ارزیابی قبل از استخدام و حین خدمت )بعضی از سازمان ها خود پرسنل را ارزیابی می کنند( معاینه دانش آموزان سالی یک مرتبه توسط پزشک عمومی به خصوص در روستاها معاینات دوره ای خانم های واجد شرایط تنظیم خانواده )سنین باروری( سالی یک مرتبه 3 16 در سال 1385 پزشکان خانواده موظف شدند که همه مردم روستا ها را از ارگان و وضعیت عمومی بررسی نمایند دستورالعمل جامعی ارائه نشد وکیفیت بررسی ضعیف بود )سواالت کلی( از سال 1393 برنامه جامع غربالگری سالمت تهیه و ابتدا در روستا ها آغاز شد در این برنامه ها همه ابعاد روحی و جسمی مورد توجه قرار گرفت. بتدریج در شهرها )ابتدا حاشیه( نیز اجرا می کنند. ) هر گروه سنی فرم متفاوتی دارد. مردان )سبا( سال تا جوانان )سما( سال )باالی سالمندان

5 5 برنامه سالمت بانوان ایرانی)سبا(

6 6

7 7

8 8

9 9

10 10

11 11

12 12

13 13

14 14

15 15

16 16

17 17

18 18

19 19

20 20

21 21

22 22 US. Preventive Services Task Force (USPSTF)

23 23

24 24 Grade Definition Suggestions for Practice A The USPSTF recommends the service. There is high certainty that the net benefit is substantial. Offer or provide this service. B The USPSTF recommends the service. There is moderate certainty that the net benefit is moderate to substantial. Offer or provide this service. C There is at least moderate certainty that the net benefit is small. Offer or provide this service for selected patients depending on individual circumstances. D There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits. Discourage the use of this service. I The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the service. If the service is offered, patients should understand : the uncertainty about the balance of benefits and harms.

25 Obesity in Adults 25

26 26 Population Adults aged 18 years or older Recommendation - Screen for obesity - Patients with a body mass index (BMI) of 30 kg/m2 or higher Grade B

27 Tobacco use 27

28 28 Population Adults age 18 years Recommendatio n Ask about tobacco use. Provide tobacco cessation interventions to those who use tobacco products. Grade A

29 29 Population Pregnant women of any age Recommendatio n Ask about tobacco use. Provide augmented pregnancy-tailored counseling for women who smoke. Grade A

30 30 Combination therapy with counseling and medications is more effective than either component alone. Pharmacotherapy FDA approved pharmacotherapy includes: Nicotine Replacement Therapy Sustained-release Bupropion Varenicline The USPSTF found inadequate evidence to evaluate the safety or efficacy of pharmacotherapy during pregnancy.

31 Alcohol Misuse 31

32 32 Population Adults age 18 years Recommendation Screen for alcohol misuse and provide brief behavioral counseling Grade B

33 Cervical Cancer 33

34 34 Population Women younger than age 21 Recommendation Do not screen Grade D

35 35 Population Women ages 21 to 65 Recommendation Screen with cytology (Pap smear) every 3 years Grade A

36 36 Population Women ages 30 to 65 Recommendatio n Screen with cytology every 3 years or contesting (cytology/hpv testing) every 5 years Grade A

37 37 Population Women younger than age 30 Recommendation Do not screen with HPV testing (alone or with cytology) Grade D

38 38 Population Women older than age 65 who have had adequate prior Screening and are not high risk Recommendation Do not screen Grade D

39 39 Population Recommendation Women after hysterectomy with removal of the cervix and with no history of high-grade pre-cancer or cervical cancer Do not screen Grade D

40 Breast Cancer 40

41 41 Population Women aged years Recommendation Screen every 2 years Grade B

42 42 Population Women aged 75 years Recommendation No recommendation Grade I (Insufficient Evidence)

43 43 Timing of Screening Evidence indicates that biennial screening is optimal.

44 Hypertension 44

45 Population Adults aged 18 and older 45 Recommendation Screen for high blood pressure Grade A Screening every 2 years with BP <120/80 Screening Tests Screening every year with SBP of mmhg or DBP of mmhg

46 Lipid disorders 46

47 47 Population Recommendatio n Grade Men age 35 years and older who are at increased risk for coronary heart disease (CHD) Women age 45 years and older who are at increased risk for coronary heart disease (CHD) Screen for lipid disorders A

48 48 The Reasonable options for screening include every 5 years Shorter intervals for people who have lipid levels close to those warranting therapy Timing of Screening Longer intervals for those not at increased risk who have had repeatedly normal lipid levels Screening may be appropriate in older people who have never been screened Repeated screening is less important in older people because lipid levels are less likely to increase after age 65 years

49 Diabetes Mellitus 49

50 50 Population adults aged 40 to 70 years who are overweight or obese Recommendation Screen for type 2 diabetes mellitus Grade B

51 51 Aspirin for the Prevention of Cardiovascular Disease and colorectal cancer

52 Population adults aged 50 to 59 years 52 who have a 10% or greater 10-year cardiovascular risk are not at increased risk for bleeding have a life expectancy of at least 10 years are willing to take low-dose aspirin daily for at least 10 years Recommendation Encourage aspirin use Grade B

53 53

54 Colorectal Cancer 54

55 55 Population Adults age 50 to 75 years Recommendation Screen for colorectal cancer Grade A

56 56 Population Adults age 76 to 85 years Recommendation Do not automatically screen. Grade C

57 57 Population Adults older than 85 Recommendation Do not screen Grade D

58 58 Screening Tests High sensitivity FOBT, sigmoidoscopy with FOBT, colonoscopy Other Relevant Recommendations The USPSTF recommends against the use of nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer.

59 59 Intervals for recommended screening strategies: Screening Intervals Annual screening with high-sensitivity fecal occult blood testing. Sigmoidoscopy every 5 years, with high-sensitivity fecal occult blood testing every 3 years. Screening colonoscopy every 10 years.

60 Osteoporosis 60

61 Population Women age 65 years without previous known fractures or secondary causes of osteoporosis 61 Women age <65 years whose 10-year fracture risk is 65 years old white woman without additional risk factors Recommendation Screen for osteoporosis Grade B

62 62

63 63 Screening Tests Current diagnostic and treatment criteria rely on: dual-energy x-ray absorptiometry of the hip and lumbar spine Timing of Screening Evidence is lacking about optimal intervals for repeated screening.

64 Abdominal Aortic Aneurysm 64

65 65 Population Men Ages 65 to 75 Years who Have Ever Smoked Recommendation Screen for AAA Grade B

66 66 Population Men Ages 65 to 75 Years who Have Never Smoked Recommendation Screen for AAA Grade C

67 67 Women Ages 65 to 75 Years who Have Ever Smoked Population Recommendation Screen for AAA Grade I

68 68 Population Women Who Have Never Smoked Recommendatio n Screen for AAA Grade D

69 69 Screening Tests Ultrasonography